Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H10BrN3O |
| Molecular Weight | 316.153 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
BrC1=CC=C2NC(=O)CN=C(C3=CC=CC=N3)C2=C1
InChI
InChIKey=VMIYHDSEFNYJSL-UHFFFAOYSA-N
InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01558 | https://www.ncbi.nlm.nih.gov/pubmed/639854 | https://www.ncbi.nlm.nih.gov/pubmed/6124947 | https://www.ncbi.nlm.nih.gov/pubmed/2570451 | https://www.ncbi.nlm.nih.gov/pubmed/24241181
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01558 | https://www.ncbi.nlm.nih.gov/pubmed/639854 | https://www.ncbi.nlm.nih.gov/pubmed/6124947 | https://www.ncbi.nlm.nih.gov/pubmed/2570451 | https://www.ncbi.nlm.nih.gov/pubmed/24241181
Bromazepam (marketed under several brand names, including Lectopam, Lexotan, Lexilium, Lexaurin, Brazepam, Rekotnil, and Lexotanil)[1] is a benzodiazepine derivative drug, patented by Roche in 1963 and developed clinically in the 1970s. It is mainly an anti-anxiety agent with similar side effects to diazepam (Valium). In addition to being used to treat anxiety or panic states, bromazepam may be used as a premedicant prior to minor surgery. Bromazepam typically comes in doses of 3 mg and 6 mg tablets.[5] Bromazepam is contraindicated and should be used with caution in women who are pregnant, the elderly, patients with a history of alcohol or other substance abuse disorders and children. Prolonged use of bromazepam causes tolerance and may lead to both physical and psychological dependence on the drug, and as a result, it is a medication which is controlled by international law. Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing the inhibitory effects of GABA. Bromazepam is a long-acting benzodiazepine and is lipophilic and metabolized hepatically via oxidative pathways.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of bromazepam on stress-induced gastric ulcer in rats and its relation to brain neurotransmitters. | 2001 Dec |
|
| Hypothermia and undressing associated with non-fatal bromazepam intoxication. | 2001 Dec 27 |
|
| Benzodiazepine withdrawal-induced catatonia. | 2001 Jan |
|
| [Prescriptions and consumption of hypnotic and anxiolytic drugs in the South University Hospital of Marseille]. | 2001 Jan-Feb |
|
| [44-year-old patient with thrombocytopenia, multiple organ failure and disseminated intravascular coagulation caused by drug poisoning with paracetamol, metamizole, benzodiazepines and alcohol in attempted suicide]. | 2001 Jun |
|
| Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. | 2002 Apr |
|
| Quantitation using GC-TOF-MS: example of bromazepam. | 2002 Aug 14 |
|
| Accidental bromazepam intoxication in a dog. | 2002 Dec 7 |
|
| Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: an application of electroencephalography as the pharmacodynamic method. | 2002 Feb |
|
| Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. | 2002 Mar 28 |
|
| Study on the inclusion complexes of bromazepam with beta- and beta-hydroxypropyl-cyclodextrins. | 2002 May 15 |
|
| Drug-induced sweat gland necrosis in a non-comatose patient: a case presentation. | 2003 Jul |
|
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | 2003 Nov 17 |
|
| Acute fatal poisoning with cyamemazine. | 2003 Oct 14 |
|
| Efficacy of antiepileptic drugs in patients with benign convulsions with mild gastroenteritis. | 2004 Apr |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
| Bromazepam determination in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry: a highly sensitive and specific tool for bioequivalence studies. | 2004 Feb |
|
| Pattern of substance use among secondary school students in Rivers State. | 2004 Jan-Mar |
|
| [Methcathinone poisoning associated with bromazepam and alcohol]. | 2004 Mar-Apr |
|
| Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. | 2004 Oct |
|
| Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. | 2004 Oct 15 |
|
| Determination of bromazepam, clonazepam and metabolites after a single intake in urine and hair by LC-MS/MS. Application to forensic cases of drug facilitated crimes. | 2004 Oct 29 |
|
| Hair to document drug-facilitated crimes: four cases involving bromazepam. | 2004 Sep |
|
| Comparison of capillary electrophoresis and reversed-phase liquid chromatography methodologies for determination of diazepam in pharmaceutical tablets. | 2005 Feb 23 |
|
| The neuropsychiatry of Parkinson's disease. | 2005 Jun |
|
| Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry. | 2005 Oct 15 |
|
| [Drug-related toxic events in the state of São Paulo, Brazil]. | 2006 Dec |
|
| Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists. | 2006 Jun |
|
| Tension-type headache with aura. | 2006 Mar |
|
| Quantification of benzodiazepines in whole blood and serum. | 2006 Nov |
|
| [The effects of bromazepam on contingent negative variation and reaction time in a visuomotor task]. | 2006 Oct 1-15 |
|
| Hyponatremia-induced seizure during carbamazepine treatment. | 2007 |
|
| How useful are prescribing indicators based on the DU90% method to distinguish the quality of prescribing between pharmacotherapy audit meetings with different levels of functioning? | 2007 Dec |
|
| Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. | 2007 Feb |
|
| Development of a validated HPLC method for the determination of four 1,4-benzodiazepines in human biological fluids. | 2007 Mar |
|
| The role of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to test blood and urine samples for the toxicological investigation of drug-facilitated crimes. | 2008 Apr |
|
| Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. | 2008 Feb 12 |
|
| Quetiapine: another drug with potential for misuse? A case report. | 2008 Jan |
|
| Thiodicarb and methomyl tissue distribution in a fatal multiple compounds poisoning. | 2008 Mar |
|
| Design and evaluation of a multi-detection system composed of ultraviolet, evaporative light scattering and inductively coupled plasma mass spectrometry detection for the analysis of pharmaceuticals by liquid chromatography. | 2008 Mar 21 |
Patents
Sample Use Guides
Adults: Depending upon severity of symptoms- 6 mg to 18 mg, in equally divided doses. Treatment may be initiated at a lower dose.
Elderly: Maximum of 3 mg in equally divided doses. Dose can be increased gradually as needed and tolerated.
Route of Administration:
Oral
500mkl of this P2-suspension (corresponding to 10mg original brain tissue) was preincubated for 5 min with Bromazepam. 25 mkl of 3H-diazepam working solution (to give a final concentration of 1.9 X 10^-9 M or approximately 14,000 cpm) was then added and the incubation continued for an additional 15 min at 37°C. The samples were then cooled in an ice bath for 30 min. IC50 values, i.e. values for 50% inhibition of specific 3H-diazepam binding, were assessed with at least 3 and up to 7 concentrations of the Bromazepam in duplicate or triplicate.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
2748
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
WHO-ATC |
N05BA08
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
||
|
WHO-VATC |
QN05BA08
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
X015L14V0O
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
m2662
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB05907MIG
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
1812-30-2
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
2441
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
399
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
140669
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
1749
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
217-322-4
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
1076465
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
BROMAZEPAM
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
DTXSID40171081
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
100000092554
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
C87454
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
2692
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL277062
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
D001960
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY | |||
|
DB01558
Created by
admin on Fri Dec 15 15:11:58 GMT 2023 , Edited by admin on Fri Dec 15 15:11:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
